NASDAQ:ENDP

Endo International Stock Forecast, Price & News

$5.93
+0.10 (+1.72 %)
(As of 04/22/2021 01:33 PM ET)
Add
Compare
Today's Range
$5.76
Now: $5.93
$6.05
50-Day Range
$5.63
MA: $7.30
$8.68
52-Week Range
$2.71
Now: $5.93
$10.89
Volume76,788 shs
Average Volume3.98 million shs
Market Capitalization$1.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Endo International logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000
Employees3,397
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 billion
Cash Flow$4.30 per share
Book Value($3.82) per share

Profitability

Net Income$-422,640,000.00

Miscellaneous

Market Cap$1.37 billion
Next Earnings Date5/7/2021 (Confirmed)
OptionableOptionable

Headlines

Endo International (NASDAQ:ENDP) Shares Gap Down to $5.89
April 20, 2021 |  americanbankingnews.com
Endo to Announce First Quarter 2021 Financial Results
April 13, 2021 |  finance.yahoo.com
Endo, Advanz Pharma Partner To Commercialize Xydalba In Canada
April 12, 2021 |  markets.businessinsider.com
Endo International (NASDAQ:ENDP) Stock Price Down 4.1%
April 8, 2021 |  americanbankingnews.com
Endo International (NASDAQ:ENDP) Shares Gap Down to $7.39
April 7, 2021 |  americanbankingnews.com
Endo International (NASDAQ:ENDP) Trading Down 7.6%
March 29, 2021 |  americanbankingnews.com
First Week of ENDP May 21st Options Trading
March 19, 2021 |  nasdaq.com
8-K: Endo International plc
March 14, 2021 |  marketwatch.com
ENDP April 23rd Options Begin Trading
March 4, 2021 |  nasdaq.com
See More Headlines

MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

574th out of 2,024 stocks

Pharmaceutical Preparations Industry

274th out of 771 stocks

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$5.93
+0.10 (+1.72 %)
(As of 04/22/2021 01:33 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Endo International (NASDAQ:ENDP) Frequently Asked Questions

Is Endo International a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Endo International stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENDP, but not buy additional shares or sell existing shares.
View analyst ratings for Endo International
or view top-rated stocks.

What stocks does MarketBeat like better than Endo International?

Wall Street analysts have given Endo International a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Endo International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Friday, May 7th 2021.
View our earnings forecast for Endo International
.

How can I listen to Endo International's earnings call?

Endo International will be holding an earnings conference call on Friday, May 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) released its earnings results on Thursday, February, 25th. The company reported $0.75 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.48 by $0.27. The company had revenue of $760.22 million for the quarter, compared to the consensus estimate of $653.83 million. Endo International had a negative net margin of 5.30% and a negative trailing twelve-month return on equity of 85.80%. During the same quarter in the prior year, the company posted $0.74 EPS.
View Endo International's earnings history
.

How has Endo International's stock been impacted by COVID-19 (Coronavirus)?

Endo International's stock was trading at $3.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ENDP shares have increased by 52.4% and is now trading at $5.93.
View which stocks have been most impacted by COVID-19
.

What guidance has Endo International issued on next quarter's earnings?

Endo International issued an update on its FY21 earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of $1.80-2.30 for the period, compared to the Thomson Reuters consensus estimate of $2.32. The company issued revenue guidance of $2.55-2.79 billion, compared to the consensus revenue estimate of $2.77 billion.

What price target have analysts set for ENDP?

8 analysts have issued 1-year price objectives for Endo International's shares. Their forecasts range from $3.00 to $12.00. On average, they expect Endo International's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts' price targets for Endo International
or view top-rated stocks among Wall Street analysts.

Who are Endo International's key executives?

Endo International's management team includes the following people:
  • Mr. Blaise Coleman, Pres, CEO & Director (Age 47, Pay $1.9M)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 49, Pay $1.82M)
  • Mr. Patrick A. Barry, Exec. VP & Pres of Global Commercial Operations (Age 53, Pay $1.47M)
  • Mr. Mark T. Bradley, Exec. VP & CFO (Age 51)
  • Mr. Robert Polke, Exec. VP & Global Head of Operations
  • Mr. Jack D. Boyle, Sr. VP, Controller & Chief Accounting Officer (Age 45)
  • Ms. Ruth Thorpe, Sr. VP of Information Technology & Chief Information Officer
  • Ms. Laure E. Park, Sr. VP of Investor Relations & Corp. Affairs
  • Ms. Susan Williamson, Sr. VP & Chief Compliance Officer
  • Ms. Tracy Basso, Chief HR Officer

What is Paul Campanelli's approval rating as Endo International's CEO?

25 employees have rated Endo International CEO Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among Endo International's employees.

Who are some of Endo International's key competitors?

What other stocks do shareholders of Endo International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

Who are Endo International's major shareholders?

Endo International's stock is owned by many different institutional and retail investors. Top institutional shareholders include Oregon Public Employees Retirement Fund (0.04%), Everence Capital Management Inc. (0.01%) and Carolina Wealth Advisors LLC (0.00%). Company insiders that own Endo International stock include International Plc Endo, Roger H Kimmel and Shane Cooke.
View institutional ownership trends for Endo International
.

Which major investors are buying Endo International stock?

ENDP stock was acquired by a variety of institutional investors in the last quarter, including Everence Capital Management Inc., Carolina Wealth Advisors LLC, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for Endo International
or or view top insider-buying stocks.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $5.93.

How much money does Endo International make?

Endo International has a market capitalization of $1.37 billion and generates $2.91 billion in revenue each year. The company earns $-422,640,000.00 in net income (profit) each year or $2.38 on an earnings per share basis.

How many employees does Endo International have?

Endo International employs 3,397 workers across the globe.

What is Endo International's official website?

The official website for Endo International is www.endo.com.

Where are Endo International's headquarters?

Endo International is headquartered at First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]


This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.